Short Interest in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Increases By 384.3%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 309,674 shares, an increase of 384.3% from the November 30th total of 63,942 shares. Based on an average trading volume of 831,701 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.3% of the shares of the company are sold short. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 831,701 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NBY. Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Apollon Wealth Management LLC acquired a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth $35,000. Finally, C2C Wealth Management LLC grew its holdings in shares of NovaBay Pharmaceuticals by 78.2% during the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 43,000 shares in the last quarter. Institutional investors own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY opened at $4.75 on Thursday. The stock’s fifty day moving average is $1.69 and its 200-day moving average is $1.35. The firm has a market capitalization of $598.55 million, a price-to-earnings ratio of -0.48 and a beta of 0.57. NovaBay Pharmaceuticals has a one year low of $0.46 and a one year high of $6.47.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.